An official American Thoracic Society Research Statement: Noninfectious lung injury after hematopoietic stem cell transplantation: Idiopathic pneumonia syndrome

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 9, 2011, Pages 1262-1279

  Panoskaltsis Mortari, Angela ^a   Griese, Matthias ^a   Madtes, David K ^a   Belperio, John A ^a   Haddad, Imad Y ^a   Folz, Rodney J ^a   Cooke, Kenneth R ^a  

^a NONE

Author keywords

Hematopoietic stem cell transplant; Lung injury; Mouse models; Pulmonary complications

Indexed keywords

CARMUSTINE; CD14 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR3; CISPLATIN; CORTICOSTEROID; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; ETANERCEPT; EXTRACELLULAR SUPEROXIDE DISMUTASE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTATHIONE; INTERLEUKIN 1BETA; KERATINOCYTE GROWTH FACTOR; LIPOPOLYSACCHARIDE; LUNG SURFACTANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEROXYNITRITE; REACTIVE NITROGEN SPECIES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNINDEXED DRUG;

ACCESSORY CELL; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE INTERSTITIAL PNEUMONITIS; ACUTE LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ANTIGEN PRESENTING CELL; BONE MARROW; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOSCOPY; CD4+ T LYMPHOCYTE; CELL DAMAGE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOMEGALOVIRUS INFECTION; DELAYED PULMONARY TOXICITY SYNDROME; DENDRITIC CELL; DIAGNOSTIC PROCEDURE; DIFFUSE ALVEOLAR HEMORRHAGE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DNA DAMAGE; DYSPNEA; EFFECTOR CELL; ENGRAFTMENT; FEVER; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; HYPOXEMIA; IDIOPATHIC PNEUMONIA SYNDROME; INCIDENCE; INFORMATION RETRIEVAL; INNATE IMMUNITY; INTERSTITIAL PNEUMONIA; LOEFFLER PNEUMONIA; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS PROTEINOSIS; LUNG BIOPSY; LUNG DISEASE; LUNG HEMORRHAGE; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; LUNG TOXICITY; LYMPHOCYTE; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDLINE; MORTALITY; MUCOPOLYSACCHARIDOSIS; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHUMAN; NONINFECTIOUS LUNG INJURY; NONMYELOABLATIVE CONDITIONING; OPPORTUNISTIC INFECTION; ORAL MUCOSITIS; OXIDATIVE STRESS; PATHOGENESIS; PEER REVIEW; PERI ENGRAFTMENT RESPIRATORY DISTRESS SYNDROME; PNEUMOCYSTIS JIROVECI; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PUBLICATION; PULMONARY CYTOLYTIC THROMBUS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RADIATION DOSE; RADIOGRAPHY; REDOX STRESS; RESPIRATORY EPITHELIUM; REVIEW; RISK FACTOR; RISK REDUCTION; SOLID TUMOR; T LYMPHOCYTE; TH17 CELL; THORAX RADIOGRAPHY; TRANSFUSION RELATED ACUTE LUNG INJURY; TRAUMATIC BRAIN INJURY; UMBILICAL CORD BLOOD; VASCULAR ENDOTHELIUM; WHOLE BODY RADIATION;

ANIMALS; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICE; PNEUMONIA; SOCIETIES, MEDICAL; SYNDROME; UNITED STATES;

EID: 79955518697     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.2007-413ST     Document Type: Review

References (230)

1. Clark JGHJ, Hertz MI, Parkman R, Jensen L, Peavy HH. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147:1601-1606. (Pubitemid 23160570)
2. Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, Fredricks DN, Corey L. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006;144:344-349.
3. Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 1993;147: 1393-1400. (Pubitemid 23160534)
4. Shankar G, Cohen DA. Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. Int J Exp Pathol 2001;82:101-113. (Pubitemid 32681937)
5. Clark JG, Madtes DK, Hackman RC, Chen W, Cheever MA, Martin PJ. Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol 1998;161:1913-1920. (Pubitemid 28387614)
6. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996;88:3230-3239.
7. Panoskaltsis-Mortari A, Taylor PA, Yaeger TM, Wangensteen OD, Bitterman PB, Ingbar DH, Vallera DA, Blazar BR. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest 1997;100:1015-1027. (Pubitemid 27386285)
8. Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999;27:1800-1806. (Pubitemid 29455107)
9. Shankar G, Scott Bryson J, Darrell Jennings C, Kaplan AM, Cohen DA. Idiopathic pneumonia syndrome after allogeneic bone marrow transplantation in mice: role of pretransplant radiation conditioning. Am J Respir Cell Mol Biol 1999;20:1116-1124. (Pubitemid 129503229)
10. Della Volpe A, Ferreri AJ, Annaloro C, Mangili P, Rosso A, Calandrino R, Villa E, Lambertenghi-Deliliers G, Fiorino C. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys 2002;52:483-488. (Pubitemid 34170853)
11. Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, Brewer JP, Ferrara JL. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000;70:272-279. (Pubitemid 30602742)
12. Wingard JR, Mellits ED, Sostrin MB, Chen DY, Burns WH, Santos GW, Vriesendorp HM, Beschorner WE, Saral R. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine (Baltimore) 1988;67:175-186.
13. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis 1982;4:1119-1132.
14. Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara JL, Uberti J, Cooke KR. Etanercept (enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:395-400.
15. Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, Maloney DG, Deeg HJ, Martin PJ, Storb RF, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003;102:2777-2785. (Pubitemid 37248846)
16. Keates-Baleeiro J, Moore P, Koyama T, Manes B, Calder C, Frangoul H. Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant 2006;38:285-289. (Pubitemid 44203778)
17. Huisman C, van der Straaten HM, Canninga-van Dijk MR, Fijnheer R, Verdonck LF. Pulmonary complications after T-cell-depleted allogeneic stem cell transplantation: Low incidence and strong association with acute graft-versus-host disease. Bone Marrow Transplant 2006;38:561-566. (Pubitemid 44509549)
18. Patriarca F, Skert C, Bonifazi F, Sperotto A, Fili C, Stanzani M, Zaja F, Cerno M, Geromin A, Bandini G, et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006;91: 1268-1272. (Pubitemid 44408442)
19. Griese M, Rampf U, Hofmann D, Fuhrer M, Reinhardt D, Bender- Gotze C. Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center. Pediatr Pulmonol 2000;30:393-401.
20. Shankar G, Bryson JS, Jennings CD, Morris PE, Cohen DA. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation. Am J Respir Cell Mol Biol 1998;18:235-242. (Pubitemid 128355197)
21. Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HE, Kolb HJ, Hartz AJ, Rimm AA. Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors. Ann Intern Med 1986;104: 168-175. (Pubitemid 16134699)
22. Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997;63:1079-1086. (Pubitemid 27190970)
23. Pecego R, Hill R, Appelbaum FR, Amos D, Buckner CD, Fefer A, Thomas ED. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986;42:515-517.
24. Robbins RA, Linder J, Stahl MG, Thompson AB III, Haire W, Kessinger A, Armitage JO, Arneson M, Woods G, Vaughan WP, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989;87:511-518. (Pubitemid 19274753)
25. Carlson K, Backlund L, Smedmyr B, Oberg G, Simonsson B. Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994;14:805-811.
26. Granena A, Carreras E, Rozman C, Salgado C, Sierra J, Algara M, Rovira M, Valls A. Interstitial pneumonitis after BMT: 15 years experience in a single institution. Bone Marrow Transplant 1993;11: 453-458. (Pubitemid 23203893)
27. Rubio C, Hill ME, Milan S, O'Brien ME, Cunningham D. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997;75:1044-1048. (Pubitemid 27122624)
28. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;32:515-522. (Pubitemid 37160968)
29. Bilgrami SF, Metersky ML, McNally D, Naqvi BH, Kapur D, Raible D, Bona RD, Edwards RL, Feingold JM, Clive JM, et al. Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. Ann Pharmacother 2001;35:196-201. (Pubitemid 32127130)
30. Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005;63:876-884. (Pubitemid 41400079)
31. Weiner RS, Horowitz MM, Gale RP, Dicke KA, van Bekkum DW, Masaoka T, Ramsay NK, Rimm AA, Rozman C, Bortin MM. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. Br J Haematol 1989;71:535-543. (Pubitemid 19121337)
32. Lazarus HM, Coccia PF, Herzig RH, Graham-Pole J, Gross S, Strandjord S, Gordon E, Cheung NK, Warkentin PI, Spitzer TR, et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984;64:215-220. (Pubitemid 14083878)
33. Bortin MM, Kay HE, Gale RP, Rimm AA. Factors associated with interstitial pneumonitis after bone-marrow transplantation for acute leukaemia. Lancet 1982;1:437-439. (Pubitemid 12163016)
34. Crawford SW, Longton G, Storb R. Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 1993;12:225-231. (Pubitemid 23268157)
35. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:425-434. (Pubitemid 33069620)
36. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versushost disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003;102: 3822-3828. (Pubitemid 37409407)
37. Afessa B, Peters SG. Noninfectious pneumonitis after blood and marrow transplant. Curr Opin Oncol 2008;20:227-233. (Pubitemid 351317412)
38. Watkins TR, Chien JW, Crawford SW. Graft versus host-associated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Semin Respir Crit Care Med 2005;26:482-489. (Pubitemid 41552377)
39. Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R, Phang S, Barrett A. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999;24:879-883. (Pubitemid 29500349)
40. Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:641-645. (Pubitemid 34971843)
41. Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006;12:949-953.
42. Heggen J, West C, Olson E, Olson T, Teague G, Fortenberry J, Yeager AM. Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. Pediatrics 2002;109:965-971. (Pubitemid 34493370)
43. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006;12:1038-1046. (Pubitemid 44597153)
44. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Bone Marrow Transplant 2006;38:765-768. (Pubitemid 44756447)
45. Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, Blazar BR, Orchard PJ, Cornfield DN, Grewal SS, Peters C, Regelmann WE, Milla CE, et al. Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation in patients with inherited metabolic storage disorders. Biol Blood Marrow Transplant 2006;12:430-437. (Pubitemid 43380960)
46. Salih ZN, Akhter A, Akhter J. Specificity and sensitivity of hemosiderinladen macrophages in routine bronchoalveolar lavage in children. Arch Pathol Lab Med 2006;130:1684-1686. (Pubitemid 44683798)
47. Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant 2000;26:539-543.
48. Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ, Suffredini A, Childs R. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant 2005;11:542-550. (Pubitemid 40862451)
49. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996;18:177-184. (Pubitemid 26289651)
50. Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:1299-1303. (Pubitemid 32655399)
51. Nurnberger W, Willers R, Burdach S, Gobel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 1997;74:221-224. (Pubitemid 27230687)
52. Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998;157:565-573. (Pubitemid 28090551)
53. Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, Rizk NW, Wong RM, Blume KG, Hu WW. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6:387-394.
54. Bhalla KS, Wilczynski SW, Abushamaa AM, Petros WP, McDonald CS, Loftis JS, Chao NJ, Vredenburgh JJ, Folz RJ. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000;161:17-25. (Pubitemid 30055897)
55. McGaughey DS, Nikcevich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, et al. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2001;7:274-278. (Pubitemid 32591298)
56. Beschorner WE, Saral R, Hutchins GM, Tutschka PJ, Santos GW. Lymphocytic bronchitis associated with graft-versus-host disease in recipients of bone-marrow transplants. N Engl J Med 1978;299:1030-1036. (Pubitemid 9050580)
57. Zhu KE, Hu JY, Zhang T, Chen J, Zhong J, Lu YH. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008;81: 461-466.
58. Piguet PF, Grau GE, Collart MA, Vassalli P, Kapanci Y. Pneumopathies of the graft-versus-host reaction: alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 1989;61:37-45. (Pubitemid 19203851)
59. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995;26: 668-675.
60. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
61. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 1988;72:621-627.
62. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, Clark JG. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003;168:208-214. (Pubitemid 36920975)
63. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003;9: 657-666. (Pubitemid 38351785)
64. Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, Bredeson CN, Horowitz MM. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005;128:153-161. (Pubitemid 40994467)
65. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, Nishimura M. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003;102:4236-4242. (Pubitemid 37487013)
66. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:749-759. (Pubitemid 46902446)
67. Patriarca F, Skert C, Sperotto A, Damiani D, Cerno M, Geromin A, Zaja F, Stocchi R, Prosdocimo S, Fili C, et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004;33:751-758. (Pubitemid 38499931)
68. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR. T-lymphocyte production of macrophage inflammatory protein- 1alpha is critical to the recruitment of CD8 (1) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000;96: 2973-2980.
69. Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 2007;176:713-723. (Pubitemid 47503080)
70. Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA, Moore BB, Kuziel WA, Liu C, Cooke KR. Blockade of CXCR3 receptor:Ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol 2004;173:2050-2059. (Pubitemid 38971642)
71. Bhalla KS, Folz RJ. Idiopathic pneumonia syndrome after syngeneic bone marrow transplant in mice. Am J Respir Crit Care Med 2002; 166:1579-1589. (Pubitemid 36015953)
72. Panoskaltsis-Mortari A, Ingbar DH, Jung P, Haddad IY, Bitterman PB, Wangensteen OD, Farrell CL, Lacey DL, Blazar BR. KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT. Am J Physiol Lung Cell Mol Physiol 2000;278:L988-L999. (Pubitemid 30351055)
73. Haddad IY, Panoskaltsis-Mortari A, Ingbar DH, Yang S, Milla CE, Blazar BR. High levels of peroxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells: a potential mechanism of injury after marrow transplantation. Am J Respir Cell Mol Biol 1999;20:1125-1135. (Pubitemid 129503230)
74. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998;102: 1882-1891. (Pubitemid 28533836)
75. Miklos S, Mueller G, Chang Y, Schubert TE, Holler E, Hildebrandt GC. Pulmonary function changes in experimental graft-versus-host disease of the lung. Biol Blood Marrow Transplant 2008;14:1004-1016.
76. Gerbitz A, Nickoloff BJ, Olkiewicz K, Willmarth NE, Hildebrandt G, Liu C, Kobzik L, Eissner G, Holler E, Ferrara JL, et al. A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation 2004;78:494-502. (Pubitemid 39097093)
77. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987;166:1280-1289. (Pubitemid 18051422)
78. Hildebrandt GC, Olkiewicz KM, Corrion LA, Chang Y, Clouthier SG, Liu C, Cooke KR. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004;104:586-593. (Pubitemid 38900046)
79. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-3131.
80. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990;61:351-359.
81. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lentz R, Raab H, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61:361-370. (Pubitemid 120035001)
82. Kalthoff H, Roeder C, Brockhaus M, Thiele HG, Schmiegel W. Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J Biol Chem 1993;268:2762-2766. (Pubitemid 23057907)
83. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993;150:4346-4353. (Pubitemid 23133711)
84. Tannenbaum CS, Major JA, Hamilton TA. IFN-gamma and lipopolysaccharide differentially modulate expression of tumor necrosis factor receptor mRNA in murine peritoneal macrophages. J Immunol 1993;151:6833-6839.
85. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993;74:845-853. (Pubitemid 23270604)
86. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-952. (Pubitemid 28049339)
87. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to l. monocytogenes infection. Cell 1993;73:457-467. (Pubitemid 23143346)
88. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998;95:570-575. (Pubitemid 28083784)
89. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83: 793-802.
90. Weiss T, Grell M, Hessabi B, Bourteele S, Muller G, Scheurich P, Wajant H. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J Immunol 1997;158:2398-2404. (Pubitemid 127470027)
91. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kD tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993;268:18542-18548. (Pubitemid 23273787)
92. Bigda J, Beletsky I, Brakebusch C, Varfolomeev Y, Engelmann H, Bigda J, Holtmann H, Wallach D. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med 1994; 180:445-460. (Pubitemid 24224121)
93. Grell M, Zimmermann G, Hulser D, Pfizenmaier K, Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 1994;153:1963-1972. (Pubitemid 24256665)
94. Speiser DE, Bachmann MF, Frick TW, McKall-Faienza K, Griffiths E, Pfeffer K, Mak TW, Ohashi PS. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 1997;158:5185-5190. (Pubitemid 127681221)
95. Shukla M, Yang S, Milla C, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Absence of host tumor necrosis factor receptor 1 attenuates manifestations of idiopathic pneumonia syndrome. Am J Physiol Lung Cell Mol Physiol 2005;288:L942-L949. (Pubitemid 40547922)
96. Hildebrandt GC, Olkiewicz KM, Corrion L, Clouthier SG, Pierce EM, Liu C, Cooke KR. A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome. Biol Blood Marrow Transplant 2008;14:385-396. (Pubitemid 351372746)
97. Smith S, Skerrett SJ, Chi EY, Jonas M, Mohler K, Wilson CB. The locus of tumor necrosis factor-alpha action in lung inflammation. Am J Respir Cell Mol Biol 1998;19:881-891. (Pubitemid 128354286)
98. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, SummerWR. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989;159:189-194. (Pubitemid 19049356)
99. Ulich TR, Watson LR, Yin SM, Guo KZ, Wang P, Thang H, del Castillo J. The intratracheal administration of endotoxin and cytokines: I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate. Am J Pathol 1991;138:1485-1496.
100. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90:3204-3213. (Pubitemid 27444217)
101. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992;175:405-413.
102. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-2759. (Pubitemid 30235880)
103. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001;107:1581-1589. (Pubitemid 32574644)
104. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 1990;5:373-377. (Pubitemid 20344118)
105. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993;23:540-545. (Pubitemid 23283061)
106. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, LehmacherW, Ruckdeschel G, Gleixner B, Riedner C, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011-1016. (Pubitemid 20067204)
107. Hauber HP, Mikkila A, Erich JM, Kroger N, Meyer A, Schoder V, Zander AR, Pforte A. TNFalpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study. Bone Marrow Transplant 2002;30:485-490. (Pubitemid 35331713)
108. Martin TR, Rubenfeld GD, Ruzinski JT, Goodman RB, Steinberg KP, Leturcq DJ, Moriarty AM, Raghu G, Baughman RP, Hudson LD. Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:937-944. (Pubitemid 27133406)
109. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-4055. (Pubitemid 28261965)
110. Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 1995;60:1371-1374. (Pubitemid 26005301)
111. Clark JG, Mandac JB, Dixon AE, Martin PJ, Hackman RC, Madtes DK. Neutralization of tumor necrosis factor-alpha action delays but does not prevent lung injury induced by alloreactive T helper 1 cells. Transplantation 2000;70:39-43. (Pubitemid 30490749)
112. Cooke KR, Kobzik L, Teshima T, Lowler K, Cluthier S, Ferrara J. A role for Fas-Fas ligand but not perforin mediated cytolysis in the development of experimental idiopathic pneumonia syndrome. Blood 2000;96:768a.
113. BakerMB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996;183:2645-2656. (Pubitemid 26192373)
114. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996;183:657-661. (Pubitemid 26059524)
115. Haddad IY, Ingbar D, Panoskaltsis-Mortari A, Blazar B. Activated alveolar macrophage-derived nitric oxide predicts the development of lung damage after marrow transplantation in mice. Chest 1999;116:37S.
116. Blackwell TS, Christman JW, Hagan T, Price P, Edens T, Morris PE, Wolff SN, Goodman SA, Christman BW. Oxidative stress and NFkappaB activation: norrelation in patients following allogeneic bone marrow transplantation. Antioxid Redox Signal 2000;2:93-102.
117. Cetin T, Arpaci F, Yilmaz MI, Saglam K, Ozturk B, Komurcu S, Gunay M, Ozet A, Akay C, Kilic S, et al. Oxidative stress in patients undergoing high-dose chemotherapy plus peripheral blood stem cell transplantation. Biol Trace Elem Res 2004;97:237-247. (Pubitemid 38406460)
118. Yang S, Porter VA, Cornfield DN, Milla C, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Effects of oxidant stress on inflammation and survival of iNOS knockout mice after marrow transplantation. Am J Physiol Lung Cell Mol Physiol 2001;281:L922-L930.
119. Abushamaa AM, Sporn TA, Folz RJ. Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 2002; 283:L336-L345. (Pubitemid 34803990)
120. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987;63:152-157. (Pubitemid 17107139)
121. Ziegler TR, Panoskaltsus-Mortari A, Gu LH, Jonas CR, Farrell CL, Lacey DL, Jones DP, Blazar BR. Regulation of glutathione redox status in lung and liver by conditioning regimens and keratinocyte growth factor in murine allogeneic bone marrow transplantation. Transplantation 2001;72:1354-1362. (Pubitemid 33015758)
122. Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 2004;34:561-571. (Pubitemid 39341534)
123. Qureshi MA, Girgis RE, Dandapantula HK, Abrams J, Soubani AO. Increased exhaled nitric oxide following autologous peripheral hematopoietic stem-cell transplantation: a potential marker of idiopathic pneumonia syndrome. Chest 2004;125:281-287.
124. Hehner SP, Breitkreutz R, Shubinsky G, Unsoeld H, Schulze-Osthoff K, Schmitz ML, Droge W. Enhancement of T cell receptor signaling by a mild oxidative shift in the intracellular thiol pool. J Immunol 2000;165:4319-4328.
125. Kang SK, Rabbani ZN, Folz RJ, Golson ML, Huang H, Yu D, Samulski TS, Dewhirst MW, Anscher MS, Vujaskovic Z. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2003;57: 1056-1066. (Pubitemid 37324124)
126. Rabbani ZN, Anscher MS, Folz RJ, Archer E, Huang H, Chen L, Golson ML, Samulski TS, Dewhirst MW, Vujaskovic Z. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer 2005;5:59.
127. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002; 109:707-712. (Pubitemid 34263144)
128. Borron PJ, Mostaghel EA, Doyle C, Walsh ES, McHeyzer-Williams MG, Wright JR. Pulmonary surfactant proteins A and D directly suppress CD31/CD41 cell function: evidence for two shared mechanisms. J Immunol 2002;169:5844-5850. (Pubitemid 35291688)
129. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003;115:13-23. (Pubitemid 37255314)
130. Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE, Akinbi HT. Surfactant protein B inhibits endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol 2003;28:373-378. (Pubitemid 36238015)
131. Augusto LA, Synguelakis M, Johansson J, Pedron T, Girard R, Chaby R. Interaction of pulmonary surfactant protein C with CD14 and lipopolysaccharide. Infect Immun 2003;71:61-67. (Pubitemid 36026004)
132. Kennedy M, Phelps D, Ingenito E. Mechanisms of surfactant dysfunction in early acute lung injury. Exp Lung Res 1997;23:171-189. (Pubitemid 27250511)
133. Zhu S, Ware LB, Geiser T, Matthay MA, Matalon S. Increased levels of nitrate and surfactant protein A nitration in the pulmonary edema fluid of patients with acute lung injury. Am J Respir Crit Care Med 2001;163:166-172. (Pubitemid 32097973)
134. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999;13:1455-1476. (Pubitemid 29357168)
135. Gunther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153: 176-184. (Pubitemid 26026846)
136. Yang S, Milla C, Panoskaltsis-Mortari A, Ingbar DH, Blazar BR, Haddad IY. Human surfactant protein A suppresses T cell-dependent inflammation and attenuates the manifestations of idiopathic pneumonia syndrome in mice. Am J Respir Cell Mol Biol 2001;24:527-536. (Pubitemid 32442759)
137. Yang S, Milla C, Panoskaltsis-Mortari A, Hawgood S, Blazar BR, Haddad IY. Surfactant protein A decreases lung injury and mortality after murine marrow transplantation. Am J Respir Cell Mol Biol 2002;27:297-305. (Pubitemid 34979287)
138. Nakane T, Nakamae H, Kamoi H, Koh H, Takeoka Y, Sakamoto E, Kanashima H, Nakamae M, Ohta K, Terada Y, Koh KR, Yamane T, Hino M. Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syn- drome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;42:43-49. (Pubitemid 352003423)
139. Heidinger K, Konig IR, Bohnert A, Kleinsteiber A, Hilgendorff A, Gortner L, Ziegler A, Chakraborty T, Bein G. Polymorphisms in the human surfactant protein-d (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics 2005;57:1-7. (Pubitemid 40591241)
140. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003;58:983-988. (Pubitemid 37392811)
141. Spragg RG. The future of surfactant therapy for patients with acute lung injury: new requirements and new surfactants. Biol Neonate 2002;81:20-24. (Pubitemid 34507586)
142. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005;293:470-476.
143. Watanabe T, Kawamura T, Kawamura H, Haga M, Shirai K, Watanabe H, Eguchi S, Abo T. Intermediate TCR cells in mouse lung: their effector function to induce pneumonitis in mice with autoimmunelike graft-versus-host disease. J Immunol 1997;158:5805-5814. (Pubitemid 127483987)
144. Cooke KR, KrengerW,Hill G, Martin TR, Kobzik L, Brewer J, Simmons R, Crawford JM, van den Brink MR, Ferrara JL. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 1998;92:2571-2580. (Pubitemid 28453002)
145. Chen W, Chatta GS, Rubin WD, Clark JG, Hackman RC, Madtes DK, Ligitt DH, Kusunoki Y, Martin PJ, Cheever MA. T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis. J Immunol 1998;161:909-918. (Pubitemid 28323556)
146. Burman AC, Banovic T, Kuns RD, Clouston AD, Stanley AC, Morris ES, Rowe V, Bofinger H, Skoczylas R, Raffelt N, et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007;110: 1064-1072. (Pubitemid 47267449)
147. Mauermann N, Burian J, von Garnier C, Dirnhofer S, Germano D, Schuett C, TammM, Bingisser R, Eriksson U, Hunziker L. Interferon-gamma regulates idiopathic pneumonia syndrome, a Th171CD41 Tcell- mediated graft-versus-host disease. Am J Respir Crit Care Med 2008;178:379-388.
148. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro differentiated Th17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathology. Blood 2008;113:1365-1374.
149. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141. (Pubitemid 41541791)
150. Massard G, Tongio MM, Wihlm JM, Morand G. The dendritic cell lineage: a ubiquitous antigen-presenting organization. Ann Thorac Surg 1996;61:252-258. (Pubitemid 26054408)
151. Armstrong LR, Christensen PJ, Paine R III, Chen GH, McDonald RA, Lim TK, Toews GB. Regulation of the immunostimulatory activity of rat pulmonary interstitial dendritic cells by cell-cell interactions and cytokines. Am J Respir Cell Mol Biol 1994;11:682-691.
152. Pollard AM, Lipscomb MF. Characterization of murine lung dendritic cells: similarities to langerhans cells and thymic dendritic cells. J Exp Med 1990;172:159-167. (Pubitemid 20217257)
153. Masten BJ, Yates JL, Pollard Koga AM, Lipscomb MF. Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L. Am J Respir Cell Mol Biol 1997;16:335-342. (Pubitemid 127497457)
154. Christensen PJ, Armstrong LR, Fak JJ, Chen GH, McDonald RA, Toews GB, Paine R III. Regulation of rat pulmonary dendritic cell immunostimulatory activity by alveolar epithelial cell-derived granulocyte macrophage colony-stimulating factor. Am J Respir Cell Mol Biol 1995;13:426-433.
155. van Haarst JM, de Wit HJ, Drexhage HA, Hoogsteden HC. Distribution and immunophenotype of mononuclear phagocytes and dendritic cells in the human lung. Am J Respir Cell Mol Biol 1994;10: 487-492.
156. Holt PG, Oliver J, Bilyk N, McMenamin C, McMenamin PG, Kraal G, Thepen T. Downregulation of the antigen presenting cell function (s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993;177:397-407. (Pubitemid 23117089)
157. Dupuis M, McDonald DM. Dendritic-cell regulation of lung immunity. Am J Respir Cell Mol Biol 1997;17:284-286. (Pubitemid 127500832)
158. Yousem SA, Ray L, Paradis IL, Dauber JA, Griffith BP. Potential role of dendritic cells in bronchiolitis obliterans in heart-lung transplantation. Ann Thorac Surg 1990;49:424-428. (Pubitemid 20097036)
159. Holt PG, Haining S, Nelson DJ, Sedgwick JD. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways. J Immunol 1994;153:256-261. (Pubitemid 24186538)
160. Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, Brewer JP, Ferrara JL. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J Immunol 2000;165:6612-6619.
161. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002;8:441-448.
162. Maus U, Herold S, Muth H, Maus R, Ermert L, Ermert M, Weissmann N, Rosseau S, Seeger W, Grimminger F, et al. Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol 2001;280:L58-L68.
163. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445. (Pubitemid 28135672)
164. Murphy PM, BaggioliniM, Charo IF, Hebert CA, Horuk R,Matsushima K, Miller LH, Oppenheim JJ, Power CA. International Union of Pharmacology: XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-176.
165. Hildebrandt GC, Duffner UA, Olkiewicz KM, Corrion LA, Willmarth NE, Williams DL, Clouthier SG, Hogaboam CM, Reddy PR, Moore BB, et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004;103:2417-2426. (Pubitemid 38326269)
166. Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Charo IF, Rollins BJ, Blazar BR. Post-bmt lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells. Am J Physiol Lung Cell Mol Physiol 2004;286:L284-L292. (Pubitemid 38129509)
167. Panoskaltsis-Mortari A, Strieter RM, Hermanson JR, Fegeding KV, Murphy WJ, Farrell CL, Lacey DL, Blazar BR. Induction of monocyte- and T-cell-attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation. Blood 2000;96:834-839. (Pubitemid 30616843)
168. Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Serody JS, Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 2003;101:3714-3721. (Pubitemid 36857964)
169. Hildebrandt GC, Olkiewicz KM, Choi S, Corrion LA, Clouthier SG, Liu C, Serody JS, Cooke KR. Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood 2005; 105:2249-2257. (Pubitemid 40387015)
170. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL, Luster AD, McKinnon K, Blazar BR, Serody JS. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol 2004;173:845-854. (Pubitemid 38930812)
171. Panoskaltsis-Mortari A, Hermanson JR, Haddad IY, Wangensteen OD, Blazar BR. Intercellular adhesion molecule-1 (ICAM-1, CD54) deficiency segregates the unique pathophysiological requirements for generating idiopathic pneumonia syndrome (IPS) versus graft-versus- host disease following allogeneic murine bone marrow transplantation. Biol Blood Marrow Transplant 2001;7:368-377. (Pubitemid 32799054)
172. Gerbitz A, Ewing P, Olkiewicz K, Willmarth NE, Williams D, Hildebrandt G, Wilke A, Liu C, Eissner G, Andreesen R, et al. A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome. Transplantation 2005;79:536-542. (Pubitemid 40365881)
173. Thomas C, Le Deist F, Cavazzana-Calvo M, Benkerrou M, Haddad E, Blanche S, Hartmann W, Friedrich W, Fischer A. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood 1995;86:1629-1635.
174. Cavazzana-Calvo M, Jabado N, Bordigoni P, Michel G, Haddad E, Mechinaud F, Landman-Parker J, Leblanc T, Plouvier E, Baruchel A, et al. In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia. Leuk Lymphoma 1997;28:103-112.
175. Madtes DK, Crawford SW. Lung injuries associated with graft-versus-host reactions. In: Ferrara JLM, Deeg HJ, Burakoff SL, editors. American Thoracic Society Documents 1277 Graft-vs.-host disease, 2nd ed. New York: Marcel Dekker; 1997. pp. 425-446.
176. Janin A, Deschaumes C, Daneshpouy M, Estaquier J, Micic-Polianski J, Rajagopalan-Levasseur P, Akarid K, Mounier N, Gluckman E, Socie G, et al. CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood 2002; 99:2940-2947. (Pubitemid 34525384)
177. Ratajczak P, Desveaux A, Socie G, Janin A. Alveolar hemorrhage and acute graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:1244-1245. (Pubitemid 47413016)
178. Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008;14: 23-32.
179. Finch PW, Cunha GR, Rubin JS, Wong J, Ron D. Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions. Dev Dyn 1995;203:223-240.
180. Panos RJ, Rubin JS, Csaky KG, Aaronson SA, Mason RJ. Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest 1993;92:969-977. (Pubitemid 23262421)
181. Ulich TR, Yi ES, Longmuir K, Yin S, Biltz R, Morris CF, Housley RM, Pierce GF. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 1994;93:1298-1306. (Pubitemid 24087188)
182. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58:933-939. (Pubitemid 28182461)
183. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998;92:3960-3967. (Pubitemid 28525223)
184. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS, Ferrara JL. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999;94:825-831. (Pubitemid 29323898)
185. Guo J, Yi ES, Havill AM, Sarosi I, Whitcomb L, Yin S, Middleton SC, Piguet P, Ulich TR. Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am J Physiol 1998;275: L800-L805.
186. Yi ES, Williams ST, Lee H, Malicki DM, Chin EM, Yin S, Tarpley J, Ulich TR. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol 1996;149: 1963-1970. (Pubitemid 26415215)
187. Sugahara K, Iyama K, Kuroda MJ, Sano K. Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol 1998;186:90-98. (Pubitemid 28407493)
188. Takeoka M, Ward WF, Pollack H, Kamp DW, Panos RJ. KGF facilitates repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol 1997;272:L1174-L1180.
189. Wu KI, Pollack N, Panos RJ, Sporn PH, Kamp DW. Keratinocyte growth factor promotes alveolar epithelial cell DNA repair after H2O2 exposure. Am J Physiol 1998;275:L780-L787.
190. Sugahara K, Rubin JS, Mason RJ, Aronsen EL, Shannon JM. Keratinocyte growth factor increases mRNAs for SP-A and SP-B in adult rat alveolar type II cells in culture. Am J Physiol 1995;269:L344-L350.
191. Yano T, Mason RJ, Pan T, Deterding RR, Nielsen LD, Shannon JM. KGF regulates pulmonary epithelial proliferation and surfactant protein gene expression in adult rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L1146-L1158. (Pubitemid 32009501)
192. Borok Z, Danto SI, Dimen LL, Zhang XL, Lubman RL. Na (1)-K (1)-ATPase expression in alveolar epithelial cells: upregulation of active ion transport by KGF. Am J Physiol 1998;274:L149-L158.
193. Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998;9:153-165. (Pubitemid 28376451)
194. Haddad IY, Milla C, Yang S, Panoskaltsis-Mortari A, Hawgood S, Lacey DL, Blazar BR. Surfactant protein A is a required mediator of keratinocyte growth factor after experimental marrow transplantation. Am J Physiol Lung Cell Mol Physiol 2003;285:L602-L610. (Pubitemid 37022861)
195. Haddad IY, Panoskaltsis-Mortari A, Ingbar DH, Resnik ER, Yang S, Farrell CL, Lacey DL, Cornfield DN, Blazar BR. Interactions of keratinocyte growth factor with a nitrating species after marrow transplantation in mice. Am J Physiol 1999;277:L391-L400. (Pubitemid 29415097)
196. Yang S, Panoskaltsis-Mortari A, Ingbar DH, Matalon S, Zhu S, Resnik ER, Farrell CL, Lacey DL, Blazar BR, Haddad IY. Cyclophosphamide prevents systemic keratinocyte growth factor-induced upregulation of surfactant protein A after allogeneic transplant in mice. Am J Respir Crit Care Med 2000;162:1884-1890.
197. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, Uren A, Welniak LA, Murphy WJ, Farrell CL, Lacey DL, Blazar BR. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000;96:4350-4356.
198. Yanik GA, Ho VT, Levine JE,White ES, Braun T, Antin JH, Whitfield J, Custer J, Jones D, Ferrara JL, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008;112:3073-3081.
199. Metcalf JP, Rennard SI, Reed EC, Haire WD, Sisson JH, Walter T, Robbins RA. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center bone marrow transplant group. Am J Med 1994;96:327-334. (Pubitemid 24127268)
200. DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol 2003;25:801-805. (Pubitemid 37238771)
201. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, Edwards CK III, Schuchman EH, Fuks Z, Kolesnick R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997;186:1831-1841. (Pubitemid 27524593)
202. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz- Friedman A, Cordon-Cardo C, Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293:293-297. (Pubitemid 32694744)
203. Clouthier SG, Cooke KR, Teshima T, Lowler KP, Liu C, Connolly K, Ferrara JL. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versusleukemia effect. Biol Blood Marrow Transplant 2003;9:592-603. (Pubitemid 38351791)
204. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7: 223-229. (Pubitemid 32433249)
205. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006;12:1261-1269. (Pubitemid 44858271)
206. Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006;107:2200-2207. (Pubitemid 43289407)
207. Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:67-74. (Pubitemid 350286740)
208. Weiss DJ, Berberich MA, Borok Z, Gail DB, Kolls JK, Penland C, Prockop DJ. Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation workshop. Proc Am Thorac Soc 2006;3:193-207. (Pubitemid 43668182)
209. Weiss DJ, Kolls JK, Ortiz LA, Panoskaltsis-Mortari A, Prockop DJ. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008;5:637-667. (Pubitemid 352031537)
210. Movsas B, Raffin TA, Epstein AH, Link CJ Jr. Pulmonary radiation injury. Chest 1997;111:1061-1076. (Pubitemid 27171481)
211. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259.
212. Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AR, Dicke KA. Early pulmonary toxicity after administration of highdose bcnu. Cancer Treat Rep 1981;65:39-44. (Pubitemid 11047815)
213. Kunitomi A, Arima N, Ishikawa T. Epstein-Barr virus-associated posttransplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab. Haematologica 2007;92:e49-e52.
214. Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY, Tien HF, Chang HH, Lu MY, Lin TT, Lin KH, Hsiao CH, Lin CW, Chen YC. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2008;43:315-321.
215. Akhtari M, Langston AA, Waller EK, Gal AA. Eosinophilic pulmonary syndrome as a manifestation of GVHD following hematopoietic stem cell transplantation in three patients. Bone Marrow Transplant 2008;43:155-158.
216. Gross TG, Hoge FJ, Jackson JD, Sammut PH, Warkentin PI. Fatal eosinophilic disease following autologous bone marrow transplantation. Bone Marrow Transplant 1994;14:333-337. (Pubitemid 24262563)
217. Richard C, Calavia J, Loyola I, Baro J, Cuadrado MA, Gomez-Casares MT, Zurbano F, Ondiviela R, Zubizarreta A. (Chronic eosinophilic pneumonia in a patient treated with allogenic bone marrow transplantation). Med Clin (Barc) 1994;102:462-464.
218. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC, Afessa B. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005;128:1385-1392. (Pubitemid 41324422)
219. Tomonari A, Shirafuji N, Iseki T, Ooi J, Nagayama H, Masunaga A, Tojo A, Tani K, Asano S. Acquired pulmonary alveolar proteinosis after umbilical cord blood transplantation for acute myeloid leukemia. Am J Hematol 2002;70:154-157.
220. Nishinakamura R, Nakayama N, Hirabayashi Y, Inoue T, Aud D, McNeil T, Azuma S, Yoshida S, Toyoda Y, Arai K, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptordeficient mice are normal. Immunity 1995;2:211-222.
221. Troussard X, Bernaudin JF, Cordonnier C, Fleury J, Payen D, Briere J, Vernant JP. Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax 1984;39:956-957. (Pubitemid 15211838)
222. Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989;47:989-992. (Pubitemid 19161834)
223. Williams LM, Fussell S, Veith RW, Nelson S, Mason CM. Pulmonary veno-occlusive disease in an adult following bone marrow transplantation: case report and review of the literature. Chest 1996;109: 1388-1391. (Pubitemid 26000299)
224. Ganguly S, Carrum G, Nizzi F, Heslop HE, Popat U. Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. Am J Hematol 2004;75:48-51. (Pubitemid 38040167)
225. Gulbahce HE, Pambuccian SE, Jessurun J, Woodard P, Steiner ME, Manivel JC, Hite S, Ramsay NK, Baker KS. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J Clin Pathol 2004;121:205-210. (Pubitemid 38140124)
226. Steward CG, Pellier I, Mahajan A, Ashworth MT, Stuart AG, Fasth A, Lang D, Fischer A, Friedrich W, Schulz AS. Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol 2004;124:63-71. (Pubitemid 38021624)
227. Grigg A, Buchanan M, Whitford H. Late-onset pulmonary arterial hypertension in association with graft-versus-host disease after allogeneic stem-cell transplantation. Am J Hematol 2005;80:38-42. (Pubitemid 41254266)
228. Limsuwan A, Pakakasama S, Rochanawutanon M, Hong-eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006;105:188-194.
229. Shankar S, Choi JK, Dermody TS, Head DR, Bunin N, Iannone R. Pulmonary hypertension complicating bone marrow transplantation for idiopathic myelofibrosis. J Pediatr Hematol Oncol 2004;26:393-397. (Pubitemid 38747733)
230. Uderzo C, Marraro G, Riva A, Bonanomi E, Vaj PL, Marchi PF, Locasciulli A, Masera G. Pulmonary thromboembolism in leukaemic children undergoing bone marrow transplantation. Bone Marrow Transplant 1993;11:201-203.